Home > Boards > US OTC > Medical - Healthcare >

BioCorRx Inc. (BICX)

Add BICX Price Alert      Hide Sticky   Hide Intro
Moderator: 236T568
Search This Board: 
Last Post: 10/8/2019 9:59:42 AM - Followers: 144 - Board type: Free - Posts Today: 0



About BioCorRx

Program Overview

BioCorRx (OTCBB: BICX) is an alcohol treatment and rehabilitation company on the leading edge of alcohol addiction treatment. The company has developed a treatment program that is used by various licensed alcohol addiction clinics throughout the United States.

The program consists of two components:BioCorRx has the worldwide rights (except in Australia and New Zealand) to a highly effective, proprietary implant formulation of the FDA-approved drug, naltrexone. After being surgically implanted by a medical professional, the naltrexone implant significantly reduces cravings for alcohol for as long as a year in some patients, depending on individual metabolism rates.BioCorRx also owns a life coaching program that is tailored specifically to alcoholics. Once a patient has received the implant, they are encouraged to enter the life coaching program to maximize results.

BioCorRx’s revolutionary alcohol treatment program has an 85% success rate as reported by patients in routine telephone and face to face interviews. The implant is administered as an outpatient procedure, and in most cases, patients do not need to miss more than one day of work. They are then able to enter the private life coaching program without co-workers or family members knowing, unless they so choose.


Naltrexone is a medication that blocks the effects of drugs known as opioids and was approved by the FDA in 1995 for the treatment of alcohol dependence.

Learn more about the side effects of naltrexone.

Naltrexone blocks the parts of the brain that "feel pleasure” when patients use alcohol. When these areas of the brain are blocked, patients feel significantly less cravings for alcohol and even if alcohol is used, the effects of it will be extremely limited - making sobriety the only option. Once medical intervention has reduced the physical need for alcohol, the program goes on to address the patient's psychological needs. The combination of these treatments has resulted in the highest chance of sobriety.

naltrexone implant

While other companies use naltrexone in their treatments, the drug is typically administered in oral or injection form, requiring their patients to be responsible for taking the medication or scheduling an appointment.

While some patients do well with the oral formulation, there is a drawback that it must be taken daily and a patient whose craving becomes overwhelming can obtain the euphoria simply by skipping a dose before resuming abuse. Patients who received the program developed by BioCorRx are treated with a slow release dose that can last up to year in many patients (depending on various factors such as metabolism rates), which gives the patients a higher success rate for the treatment of alcoholism.

The outpatient naltrexone implant procedure can take as little as 20 minutes under local anesthetic in some cases. Most patients can return to work or their daily routine in the same day, without the cravings for alcohol.

Mission, Vision, Values


BioCorRx is focused on providing leadership and innovation for the treatment of alcoholism by offering a high-quality, comprehensive and cost-effective recovery program that allows patients and their loved ones to celebrate freedom from the cycle of alcohol addiction. Our program is built on a strong foundation of experience and practice, allowing for an improved quality of life for recovering alcoholics.


BioCorRx strives to be the preeminent, long-term alcohol recovery program used by treatment centers around the world for alcoholics, as well as their family and friends. By providing patients a "Fresh Start" on life, they have the opportunity to live happier, healthier, more productive lives away from the damaging impact of alcohol. We have built an organization that is committed to nurturing research for cutting-edge alcohol recovery technologies and integrating those technologies with comprehensive alcohol recovery treatment programs.


BioCorRx provides the opportunity and tools to treatment centers so they can help patients live happier, healthier, and more productive lives to those suffering from alcohol addiction (as well as their family and friends) by helping them break the addiction cycle and live alcohol-free. We want patients to celebrate freedom from the past and hope for the future. Our team consists of physicians, coaches, founders and management that are committed to providing high-quality services and adherence to ethical care.

Our goal is to give our treatment center partners the ability to deliver our program in a timely, warm and compassionate way to give patients, as well as their families and friends, peace of mind. To achieve this, BioCorRx has built its program around highly-qualified alcohol addiction specialists and effective treatment solutions.

We are committed to quality and continuous improvement in order to meet our partners’ needs for an individualized program dedicated to alcohol addiction recovery.

Investors Overview

BioCorRx is uniquely poised to gain significant market share of the $22 billion annual alcohol treatment market in the US.

More than 7% of the US population ages 18 years and older or 13.8 million Americans have problems with drinking, including 8.1 million people who suffer from alcoholism. And the costs financially are staggering. Alcohol dependency and abuse costs the US over $220 billion a year. For the sake of comparison, this is greater than the amount of money spent to combat cancer ($196 billion) and obesity ($133 billion).

BioCorRx intends to distribute the program to a new clinic in the United States every 60 to 90 days. Clinics using our program are also holding discussions with major health insurance providers to pay for all or a portion of the treatment fees.

Business Model

BioCorRx’s research has discovered that demand for its services are high and that growth in highly marketed segments of the population may be achieved through partnering with additional clinic sites. The company is also exploring the sub-licensing of the program to select regions of the US and internationally.

BioCorRx's goal is to meet its growth targets through licensing opportunities by promoting its naltrexone implant product and counseling service model to existing medical clinics and treatment centers that will purchase the program and/or product from the company. In addition, Fresh Start Private intends to open corporately owned clinics in select key markets where it is deemed appropriate.

Stock Price & Charts

BioCorRx is a fully reporting company. Financial reports and other reports are available for view or by visiting the OTCBB.com online website. Audited financial reports are available quarterly.

Company Structure Details

  • Legal name: BioCorRx
    Sector: Healthcare
    Industry: Specialized Health Services
    Full Time Employees: 4
    Public Company: SEC Reporting and fully audited
    Symbol: BICX
    Exchange: OTCBB
    Outstanding: 117,800,000
    Authorized: 200,000,000
    CUSIP: 35804J102
    NAICS Code: 623220
    SIC Number: 8093
    Transfer Agent: Columbia Stock Transfer Company, 1869 E. Seltice Way #292, Post Falls, ID 83854 Tel (208) 664-3544
    CIK: 0001443863
    EIN: 26-1972677
    Year End: December 31
    State of incorporation: Nevada
    Products: Alcohol rehabilitation, exclusive naltrexone implant technology
    Address: 601 North Parkcenter Drive, Suite 103, Santa Ana, CA 92705 USA
    Investors: 858-381-4677
    Email: investors@biocorrx.com
    Website: www.biocorrx.com
Watch Jeremy Miller on Fox News!

<iframe width="560" height="315" src="; frameborder="0" allowfullscreen></iframe>www.youtube.com/embed/xhJrYqsV0VQ

<iframe width="560" height="315" src="https://www.youtube.com/watch?v=kVKgWi3_t5Y" frameborder="0" allowfullscreen></iframe>


BICX Chart

Key Executives

Kent Emry - CEO, Director
Brady Granier -COO, Director
Lourdes Felix -CFO, Director
Dr. Jorge Andrade, Jr. - Director
Neil Muller -Co-Founder and President, Director 

Locations of independently owned clinics using our Fresh Start Program

Start Fresh Recovery
720 N. Tustin Ave.
Suite 206
Santa Ana, CA 92705

Start Fresh Executive Recovery
367 E Virginia Ave
Phoenix, AZ 85004
855-393-HOPE (4673)

Fresh Start Private Florida
1415 Panther Lane
Suites 313-320
Naples, FL 34109

Start Fresh Alcohol Recovery Center
2827 S. 88th St
Omaha NE 68124

Coming Soon!

• San Francisco, California
• Chandler, Arizona
• North Scottsdale, Arizona
• Connecticut

Insider Interview Links

December 2, 2013 - thewallstreetanalyzer.com Interview with Brady Granier COO
November 14, 2013 - SmallCapVoice Interview with Kent Emry CEO
October 2, 2013 - SmallCapVoice Interview with Brady Granier COO



Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#12199  Sticky Note Scam company BICX issues FALSE AND MISLEADING press 236T568 04/11/19 02:46:18 PM
#12492   Are you saying BICX didn’t raise $6,000,000? telark 10/08/19 09:59:42 AM
#12491   actually, the big question would be as to 236T568 10/07/19 07:52:47 PM
#12490   Where do you estimate this company would be telark 10/07/19 07:49:12 PM
#12489   scam company BICX changed that figure in the 236T568 10/07/19 03:19:36 PM
#12488   But didn’t you say it was going to telark 10/07/19 01:49:38 PM
#12487   BICX files 8K after close on Friday-Massive Dilution 236T568 10/07/19 09:37:34 AM
#12486   BICX Daily Chart Golden_Cross 10/07/19 08:41:51 AM
#12485   News out - BioCorRx Announces Capital Restructuring and Golden_Cross 10/07/19 08:41:12 AM
#12483   Yikes! $2.47 again, ties 52 week low! 236T568 10/04/19 12:35:29 PM
#12482   RIP GaryWinthorpe 10/04/19 10:33:41 AM
#12481   Sure is Shaggy...got any scooby snacks? GaryWinthorpe 10/03/19 10:01:16 AM
#12480   Zoinks...this is still trading? Thirdeyeblind 10/03/19 09:47:05 AM
#12478   Agreed. They said the reason was to uplist GaryWinthorpe 10/03/19 09:04:40 AM
#12477   I really have no knowledge in BIO grants, Kizersosae 10/02/19 09:08:16 PM
#12476   My concern is that they are living off big orange 10/02/19 03:58:46 PM
#12475   Looks like one guy dumped at/near the opening. stanggt 10/02/19 12:32:13 PM
#12474   Whoaaaaa! $2.47 - New 52 week low! 236T568 10/02/19 10:50:05 AM
#12473   WTF DREAM BIG 10/02/19 10:06:23 AM
#12472   Good question. Need to ask. stanggt 09/25/19 11:48:25 AM
#12471   Is that something that will be covered by insurance? Kizersosae 09/24/19 09:05:48 PM
#12470   I have a keen interest in their weight stanggt 09/24/19 05:29:12 PM
#12469   I hear you, reaching out to IR was telark 09/13/19 10:57:41 PM
#12468   Tel, I wasn’t being critical. Someone questioned why we Leshrac528 09/13/19 10:49:23 PM
#12467   So what was your expectation? Do companies receive telark 09/13/19 09:38:58 PM
#12466   Response from IR... Leshrac528 09/13/19 03:02:38 PM
#12465   No news but a lot of promo on stanggt 09/10/19 01:33:18 PM
#12464   Kiz, good points made and is why I Fido 09/09/19 02:45:00 PM
#12463   Ya, that’s a good point. Definitely a lot Kizersosae 09/09/19 07:43:21 AM
#12462   What concerns me, is that they were awarded drugmanrx 09/07/19 08:24:14 PM
#12461   Is Brady still involved with this co? froggie77 09/07/19 02:36:26 PM
#12459   Great accomplishments! By all means don’t forget to telark 08/29/19 07:21:55 AM
#12458   So how bad are things for BICX? 236T568 08/27/19 08:38:59 PM
#12457   Yes they filed on August 14th. telark 08/24/19 05:26:52 PM
#12456   Maybe this will change for the better with telark 08/24/19 05:25:48 PM
#12455   Yes, it is a net loss. Nothing new telark 08/24/19 05:23:39 PM
#12454   I don’t believe this is anything that is telark 08/24/19 05:22:39 PM
#12453   BICX massive Negative Shareholders Equity of $3.1 million 236T568 08/23/19 03:49:28 PM
#12452   BICX - Massive Net Loss of $2.0 million 236T568 08/23/19 03:47:28 PM
#12451   BICX - only $65,976 in revenues for the 236T568 08/23/19 03:45:56 PM
#12450   BICX files 10Q for the 2nd quarter ending 236T568 08/23/19 03:44:24 PM
#12449   Ouch! $3.10 - New 52 week Low! 236T568 08/19/19 11:43:22 AM
#12448   HA - it's Friday. :) Fido 08/16/19 09:43:11 AM
#12447   Lol...once again not debating validity of your point. GaryWinthorpe 07/30/19 12:59:04 PM
#12446   Lol, they been talking about up listing just drugmanrx 07/30/19 11:40:16 AM
#12445   I also never said I believed it was GaryWinthorpe 07/30/19 11:26:14 AM
#12444   Only one of those things you listed is GaryWinthorpe 07/30/19 11:24:43 AM
#12443   Why do you believe BICX will be able drugmanrx 07/30/19 10:26:36 AM
#12442   Posted for news on uplisting...not podcast hosts thoughts. GaryWinthorpe 07/30/19 10:14:51 AM
#12440   BICX's problems continue - DISMISSES AUDITOR 236T568 07/29/19 06:34:46 PM
#12439   BICX - $4.16 million Note convertible to 318.million.common.shares 236T568 07/29/19 06:33:52 PM